Teva asks SCOTUS to overturn “skinny label” verdict on GSK drug
pharmaphorum
JULY 15, 2022
The case hinges around the concept of “ skinny labelling ” which was introduced to stop drugmakers extending the exclusivity period for their branded medicines – through a stream of new indications or patient populations – that can be protected with so-called “use” patents. The substance patent expired in 2007.
Let's personalize your content